Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 25, 2025
|% Change Since: -30.00%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
X4 Pharmaceuticals showed strong progress with the launch of XOLREMDI and international expansion efforts. Positive clinical trial results and strategic restructuring indicate potential for future growth. However, the company faces challenges with net losses, market penetration, and adjustments in clinical trial protocols.Company Guidance
During the X4 Pharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call, key metrics highlighted included the 2024 XOLREMDI sales topping $2.5 million in the 7.5 months since its mid-May launch for the treatment of WHIM syndrome. The company engaged with top-tier immunologists and hematologists, with efforts expected to increase patient finding and prescription rates. The company reported net XOLREMDI revenues of $1.4 million for the fourth quarter and $2.6 million for the full year. Research and Development (R&D) expenditures were $21.7 million for Q4 and $81.6 million for the year, while Selling, General and Administrative (SG&A) expenses were $15.1 million for Q4 and $61.5 million for the year. The net loss was $39.8 million for Q4 and $37.5 million for the full year, noting a significant income from a priority review voucher sale. Moving forward, the company has refined its global pivotal Phase 3 CN trial protocol and aims for full enrollment by Q3 or Q4 2025, with top-line data expected in the second half of 2026. The company ended 2024 with nearly $103 million in cash and cash equivalents, projecting sufficient funds to support operations into the first half of 2026.Successful Launch of XOLREMDI
X4 Pharmaceuticals launched XOLREMDI for WHIM syndrome, achieving $2.5 million in sales despite only being on the market for 7.5 months since mid-May 2024.
Positive Phase 2 Clinical Trial Results
The Phase 2 trial for mavorixafor in chronic neutropenia showed that the drug was well tolerated and increased mean absolute neutrophil counts, reducing the use of G-CSF.
Progress in International Markets
X4 Pharmaceuticals expanded its reach with two international partnerships and had its MAA accepted by the EMA for mavorixafor.
Strategic Restructuring for Cost Efficiency
A strategic restructuring was implemented to decrease spending by $30 million to $35 million annually, focusing on maximizing the opportunity for mavorixafor in chronic neutropenia.
---
XFOR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XFOR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 25, 2025 | $0.30 | $0.26 | -13.33% |
| Nov 13, 2024 | $0.59 | $0.28 | -52.54% |
| Aug 08, 2024 | $0.63 | $0.65 | +3.17% |
| May 07, 2024 | $1.20 | $1.09 | -9.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does X4 Pharmaceuticals Inc (XFOR) report earnings?
X4 Pharmaceuticals Inc (XFOR) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is X4 Pharmaceuticals Inc (XFOR) earnings time?
X4 Pharmaceuticals Inc (XFOR) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XFOR EPS forecast?
XFOR EPS forecast for the fiscal quarter 2025 (Q1) is -0.12.
---